ZYMEWORKS INC. - COMMON STOCK

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

12 Jan 2026 06:00:00 By Nasdaq GlobeNewswire

Zymeworks Outlines Strategic Priorities and Outlook for 2026

11 Jan 2026 18:00:00 By Nasdaq GlobeNewswire

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

06 Jan 2026 13:34:22 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Conferences

02 Dec 2025 16:05:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

24 Nov 2025 06:00:00 By Nasdaq GlobeNewswire

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

18 Nov 2025 01:01:00 By Nasdaq GlobeNewswire

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

18 Nov 2025 01:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

17 Nov 2025 06:00:00 By Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

06 Nov 2025 16:05:03 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

28 Oct 2025 06:00:00 By Nasdaq GlobeNewswire

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

23 Oct 2025 12:30:00 By Nasdaq GlobeNewswire

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

16 Oct 2025 06:00:00 By Nasdaq GlobeNewswire

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

13 Oct 2025 16:00:00 By Nasdaq GlobeNewswire

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

09 Oct 2025 06:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

02 Sep 2025 06:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

19 Aug 2025 06:00:00 By Nasdaq GlobeNewswire

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

11 Aug 2025 06:00:00 By Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

07 Aug 2025 16:05:03 By Nasdaq GlobeNewswire

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

28 Jul 2025 06:00:00 By Nasdaq GlobeNewswire

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

17 Jul 2025 06:00:00 By Nasdaq GlobeNewswire